204 related articles for article (PubMed ID: 29761503)
1. Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: Two pathogenetic types based study.
Yarema R; Fetsych T; Volodko N; Оhorchak M; Petronchak O; Huley R; Mylyan Y; Glehen O
J Surg Oncol; 2018 Jun; 117(8):1806-1812. PubMed ID: 29761503
[TBL] [Abstract][Full Text] [Related]
2. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
3. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.
Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spilioitis J; Torres-Melero J; Turaga K; Trout R
Ann Surg Oncol; 2014 Dec; 21(13):4195-201. PubMed ID: 24854493
[TBL] [Abstract][Full Text] [Related]
4. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.
Arjona-Sanchez A; Rodriguez-Ortiz L; Baratti D; Schneider MA; Gutiérrez-Calvo A; García-Fadrique A; Tuynman JB; Cascales-Campos PA; Martín VC; Morales R; Salti GI; Arteaga X; Pacheco D; Alonso-Gomez J; Yalkin O; Villarejo-Campos P; Sanchez-Hidalgo JM; Casado-Adam A; Cosano-Alvarez A; Rufian-Peña S; Briceño J
Ann Surg Oncol; 2019 Aug; 26(8):2595-2604. PubMed ID: 31111351
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis.
Ng JL; Ong WS; Chia CS; Tan GH; Soo KC; Teo MC
Int J Surg Oncol; 2016; 2016():2495131. PubMed ID: 27006828
[TBL] [Abstract][Full Text] [Related]
6. Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC.
Simkens GA; van Oudheusden TR; Nieboer D; Steyerberg EW; Rutten HJ; Luyer MD; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2016 Dec; 23(13):4214-4221. PubMed ID: 27027308
[TBL] [Abstract][Full Text] [Related]
7. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination.
Esquivel J; Garcia SS; Hicken W; Seibel J; Shekitka K; Trout R
J Surg Oncol; 2014 Nov; 110(6):656-60. PubMed ID: 24898451
[TBL] [Abstract][Full Text] [Related]
9. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
[TBL] [Abstract][Full Text] [Related]
11. External Validation of the Prognostic Nomogram (COMPASS) for Patients with Peritoneal Carcinomatosis of Colorectal Cancer.
Demey K; Wolthuis A; de Buck van Overstraeten A; Fieuws S; Vandecaveye V; Van Cutsem E; D'Hoore A
Ann Surg Oncol; 2017 Nov; 24(12):3604-3608. PubMed ID: 28895112
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies.
Yoon W; Alame A; Berri R
Am J Surg; 2014 Mar; 207(3):403-7; discussion 406-7. PubMed ID: 24444858
[TBL] [Abstract][Full Text] [Related]
13. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC
World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066
[TBL] [Abstract][Full Text] [Related]
14. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
Wong JF; Tan GH; Wang W; Soo KC; Teo MC
World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
[TBL] [Abstract][Full Text] [Related]
15. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
16. Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy.
Arjona-Sanchez A; Rufian-Peña S; Artiles M; Sánchez-Hidalgo JM; Casado-Adam Á; Cosano A; Thoelecke H; Ramnarine S; Garcilazo D; Briceño-Delgado J
Int J Hyperthermia; 2018 Aug; 34(5):570-577. PubMed ID: 29298538
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
Teo MC; Tan GH; Tham CK; Lim C; Soo KC
Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
[TBL] [Abstract][Full Text] [Related]
18. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
[TBL] [Abstract][Full Text] [Related]
19. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.
Gómez-Ruiz ÁJ; González-Gil A; Gil J; Navarro-Barrios Á; Alconchel F; Gil E; Martínez J; Nieto A; Barceló F; Cascales-Campos PA
Clin Exp Metastasis; 2019 Oct; 36(5):433-439. PubMed ID: 31270731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]